68Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases of recurrent prostate cancer after initial surgery-Reference-Cited by-同舟云学术

68Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases of recurrent prostate cancer after initial surgery

Published:2019-09-27 Issue:2 Volume:59 Page:149-156
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Marzec J.¹^ORCID,Becker J.¹,Paulsen F.¹,Wegener D.¹,Olthof S.-C.²,Pfannenberg C.²,Schwenck J.³⁴,Bedke J.⁵^ORCID,Stenzl A.⁵,Nikolaou K.²,la Fougère C.³⁶⁴,Zips D.¹⁶,Müller A.-C.¹^ORCID

Affiliation:

1. Department of Radiation Oncology, Eberhard Karls University, Tübingen, Germany;

2. Department of Diagnostic and Interventional Radiology, Eberhard Karls University Tübingen, Tübingen, Germany;

3. Department of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, Eberhard Karls University Tübingen, Tübingen, Germany;

4. Cluster of Excellnence iFIT (EXC 2180) “Image Guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, Germany

5. Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany;

6. German Cancer Consortium (DKTK), Partner Site Tübingen; and German Cancer Research Center (DKFZ), Heidelberg, Germany;

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2019.1669816

Reference37 articles.

1. NCCN Guidelines® & Clinical Resources [Internet]. Pennsylvania (US): National Comprehensive Cancer Network; 2019. [cited Aug 12]. Available from: www.nccn.org

2. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms Version 5.0 [German S3-Guideline] [Internet] Berlin (DE): Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF; 2019. [cited Aug 12]. Available from: www.leitlinienprogramm-onkologie.de

3. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

4. Oligometastases.

5. Stereotactic body radiotherapy for oligometastases

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer: current and emerging applications;Abdominal Radiology;2024-02-22

2. A systematic review and meta-analysis on non-metastatic castration resistant prostate cancer: The radiation oncologist's perspective;Seminars in Oncology;2022-10

3. Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial;BMJ Open;2022-09

4. PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer;Clinical and Translational Radiation Oncology;2021-09

5. Progression-free survival in patients with 68Ga-PSMA-PET-directed SBRT for lymph node oligometastases;Acta Oncologica;2021-07-29